Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IONSBullishIndustry Newsnews

High materiality9/10

Ionis and Roche Announce Positive Phase 3 Interim Results for sefaxersen in IgA Nephropathy

Sep 23, 2026, 1:20 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 3 interim data meeting the primary endpoint tends to boost sentiment on the lead program and partner collaboration, potentially lifting Ionis' valuation and igniting upside on anticipated regulatory milestones, subject to full data durability and safety.

AI summary

What happened, with direct paths to the underlying reporting

Ionis Pharmaceuticals and Roche disclosed prespecified interim Phase 3 IMAgINATION results for sefaxersen in adults with primary IgA nephropathy, showing a statistically significant reduction in 24-hour urine protein versus placebo at 37 weeks. While full durability and safety data remain pending, the outcome validates Ionis' antisense approach in nephrology and could accelerate the program's regulatory trajectory and potential value realization.

Ionis and Roche report positive sefaxersen results in IgAN. Interim data show primary endpoint success.
Primary endpoint met: significant proteinuria reduction at 37 weeks.
Results prespecified interim; full data due later.
IgAN program expands sefaxersen potential in nephrology.
Roche collaboration supports Ionis' antisense platform.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.